



Same Science,
New Look



Developed to
Optimize Co

o
omfort.



We Heard You

Our journey began with a commitment to realizing the full potential of regenerative therapy. We recognized the need to enhance our current product offering, providing physicians with a multitude of Cryopreserved Amniotic Membrane (CAM) options for their patients.

We're proud to introduce a CAM solution that will expand patient access while also providing physicians with a simple storage solution.



**Dry Eye is a
progressive disease.**


Your lack of options has forced
you to wait to intervene at the
end of the road.

The Wait is Over

CAM360 AmnioGraft™ (CAM360 AG) is a ringless, cryopreserved amniotic membrane that can be stored at room temperature. CAM360 AG also has an adhesive property, allowing the CAM to stick and stay under a Collagen Shield (CS) or Bandage Contact Lens (BCL).¹

CAM has been shown to reduce signs and symptoms associated with Dry Eye Disease.²⁻⁴ It exerts anti-inflammatory, anti-scarring, and anti-angiogenic actions that help promote the body's healing capabilities.





CAM360 AG is the only hydrated amniotic membrane developed to optimize comfort.

Key Product Features




Cryopreserved



Ringless

Size \varnothing 12mm



Shelf-Stable




Adhesive Property¹

Preserving HC-HA/PTX3

Key Orchestrator

Heavy Chain – Hyaluronic Acid Pentraxin 3 (HC-HA/PTX3)



HC-HA/PTX3 is the key matrix found within fresh and cryopreserved tissues that is responsible for Amniotic Membrane's (AM) therapeutic benefits.⁵

Cryopreserved AM is comparable to fresh tissue based on the retention of key architectural and biochemical components essential for the therapeutic actions of the tissue.⁶

Keeping You Compliant

Cryopreserved AM is recognized by the FDA⁷ for:

- Anti-inflammation
- Anti-scarring
- Promoting Healing



Storage Made Easy

BioTissue's proprietary CryoTek® and SteriTek® preservation methods are the only proven processing methods that retain the HC-HA/PTX3 found in fresh tissue.⁸

Our processing methods were specifically designed to optimize preservation while also providing efficiencies in handling, storage, and product application.

SteriTek Offering the Best of Both Worlds

Our SteriTek preservation process yields a **shelf-stable product, protecting the bioactive components of the tissue without heat dehydration.**



The tissue is cleaned, processed, and packaged in a manner similar to our CryoTek cryopreservation process.

The tissue then undergoes our SteriTek preservation process, which utilizes saline as its storage medium, yielding a shelf-stable product without heat dehydration of the tissue.

The tissue is terminally sterilized using gamma irradiation, yielding a fully hydrated product that can be stored at a controlled room temperature.

The CryoTek and SteriTek methods protect the key matrix of the tissue that orchestrates the regenerative healing process.

Our proprietary processing method preserves the tissue's unique, **adhesive property** allowing CAM360 to **stick and stay** under a Bandage Contact Lens (BCL).¹

Increasing Patient Access

Our dedication to improving patient lives guides every decision we make. CAM360 AG will empower physicians to extend the healing benefits of our tissue to more patients in need.



Approx.

50 MILLION

people in the U.S. suffer from
Dry Eye Disease (DED)⁹


Nearly

50%

of people surveyed with DED
claim their daily lives are
heavily impacted by it¹⁰



Resources to Set You Up for Success



CAM360 AG
Application Video



Keep up with the latest
on CAM360 AG

References

1. Data on file.
2. John, T., Tighe, S., Sheha, H., Hamrah, P., Salem, Z. M., Cheng, A., ... & Rock, N. D. (2017). Corneal nerve regeneration after self-retained cryopreserved amniotic membrane in dry eye disease. *Journal of ophthalmology*, 2017.
3. McDonald, M. B., Sheha, H., Tighe, S., Janik, S. B., Bowden, F. W., Chokshi, A. R., ... & McMurren, B. J. (2018). Treatment outcomes in the DRy eye amniotic membrane (DREAM) study. *Clinical Ophthalmology*, 677-681.
4. Cheng, A. M., Zhao, D., Chen, R., Yin, H. Y., Tighe, S., Sheha, H., ... & Tseng, S. C. (2016). Accelerated restoration of ocular surface health in dry eye disease by self-retained cryopreserved amniotic membrane. *The Ocular Surface*, 14(1), 56-63.
5. Tighe, S., Mead, O. G., Lee, A., & Tseng, S. C. G. (2020). Basic science review of birth tissue uses in ophthalmology. *Taiwan Journal of Ophthalmology*, 10(1), 3-12.
6. Tan EK, Cooke M, Mandrycky C, et al. Structural and biological comparison of cryopreserved and fresh amniotic membrane tissues. *J Biomater Tissue Eng*. 2014;(4):379-388.
7. Request for Designation: Amniotic Membrane for Ocular Surface Reconstruction. *Food and Drug Administration*. November 26, 2001. Accessed March 1, 2024. Available from <https://www.fda.gov/media/74873/download>.
8. Cooke, M., Tan, E. K., Mandrycky, C., He, H., O'Connell, J., & Tseng, S. C. G. (2014). Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. *Journal of Wound Care*, 23(10), 465-476.
9. Dry Eye Statistics in 2021 - Dry Eye Directory. n.d. *Dryeyedirectory.com*. <https://dryeyedirectory.com/dry-eye-statistics/>.
10. Dry Eye Jacksonville: Dry Eye Treatment Jacksonville, FL. *Bowden Eye & Associates*, June 8, 2023. <https://www.bowdeneye.com/dry-eye-jacksonville/>.

Report any feedback or unexpected reactions by emailing **Customerfeedback@biotissue.com**